---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-058795"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2026-05-19T14:32:30+00:00"
generated_at: "2026-05-19T14:44:19.365868+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company

## Summary
- Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.
- Concurrent $290M private placement led by Fairmount; funds operations through 2028.
- Mentari's lead programs: MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) targeting migraine prevention.
- Pre-Merger InMed shareholders receive Contingent Value Rights (CVRs) for net proceeds from legacy asset sales.
- Closing conditions include $150M+ pre-closing financing, shareholder approvals, and Nasdaq listing.

## SEC filing metadata
- accession: 0001213900-26-058795
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2026-05-19T14:32:30+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/0001213900-26-058795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/ea0291482-8k425_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-058795
- JSON: https://secwatch.observer/filing/0001213900-26-058795.json
- Plain text: https://secwatch.observer/filing/0001213900-26-058795.txt

## Key facts
- Material Agreements
  InMed Pharmaceuticals Inc. entered into Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. valued at equity value of $125,000,000 (effective 2026-05-19).
  - Action: entry
  - Agreement: merger
  - Counterparty: Mentari Therapeutics, Inc.
  - Value: equity value of $125,000,000
  - Effective: 2026-05-19
  source text: ub, the “ Merger Subs ”), and Mentari Therapeutics, Inc., a Delaware corporation (“ Mentari ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”), pursuant to which, among other matters
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/0001213900-26-058795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.